Henry Schein, Inc. Expected to Post Q3 2024 Earnings of $1.16 Per Share (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Investment analysts at William Blair decreased their Q3 2024 earnings estimates for shares of Henry Schein in a report issued on Tuesday, August 6th. William Blair analyst B. Vazquez now forecasts that the company will earn $1.16 per share for the quarter, down from their prior estimate of $1.32. The consensus estimate for Henry Schein’s current full-year earnings is $5.16 per share. William Blair also issued estimates for Henry Schein’s Q4 2024 earnings at $1.25 EPS, FY2024 earnings at $4.74 EPS, Q1 2025 earnings at $1.26 EPS, Q2 2025 earnings at $1.30 EPS, Q3 2025 earnings at $1.43 EPS, Q4 2025 earnings at $1.48 EPS and FY2025 earnings at $5.13 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. The business had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.27 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. Henry Schein’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the company posted $1.31 EPS.

A number of other analysts have also recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $86.00 target price on shares of Henry Schein in a research note on Friday, June 21st. Robert W. Baird lowered their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group lowered their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Finally, Barrington Research decreased their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Henry Schein presently has a consensus rating of “Hold” and an average target price of $77.90.

Henry Schein Stock Up 1.1 %

NASDAQ HSIC traded up $0.78 during trading hours on Thursday, reaching $68.94. 2,399,686 shares of the company’s stock were exchanged, compared to its average volume of 1,227,769. The company’s 50-day moving average is $67.73 and its two-hundred day moving average is $71.57. Henry Schein has a one year low of $60.01 and a one year high of $82.63. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The company has a market capitalization of $8.83 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87.

Institutional Investors Weigh In On Henry Schein

Large investors have recently made changes to their positions in the stock. Summit Securities Group LLC acquired a new stake in Henry Schein during the 2nd quarter valued at $31,000. Beach Investment Counsel Inc. PA acquired a new stake in Henry Schein during the 2nd quarter valued at $37,000. Blue Trust Inc. lifted its holdings in Henry Schein by 104.2% during the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after purchasing an additional 475 shares during the last quarter. Mather Group LLC. acquired a new stake in Henry Schein during the 1st quarter valued at $97,000. Finally, Palisade Asset Management LLC acquired a new stake in Henry Schein during the 1st quarter valued at $113,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.